DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

TAO Synergies Inc.

NasdaqCM:TAOX Stock Report

Market Cap: US$27.4m

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

TAO Synergies Past Earnings Performance

Past criteria checks 0/6

TAO Synergies's earnings have been declining at an average annual rate of -18.4%, while the Software industry saw earnings growing at 31.8% annually. Revenues have been growing at an average rate of 98.4% per year.

Key information

-18.35%

Earnings growth rate

54.95%

EPS growth rate

Software Industry Growth17.33%
Revenue growth rate98.40%
Return on equity-96.28%
Net Margin-2,763.47%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Analysis Article • Jul 30

Companies Like TAO Synergies (NASDAQ:TAOX) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Apr 07

Is TAO Synergies (NASDAQ:TAOX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 13

TAO Synergies (NASDAQ:TAOX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 20

We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 10

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Nov 17

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer’s Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistically significant improvement vs placebo. Based on learnings from the first two trials, a third trial is underway with a longer duration (6 vs 3 months) and a narrowed patient population – read-out targeted for 2H2022. The probability of success in the current trial is reasonable based on the learnings from the first two trials, but the small size is a risk that a statistically-significant improvement may not be achieved. The potential large upside affords a highly positive asymmetric risk-reward.
Analysis Article • Oct 05

Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 09

We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Revenue & Expenses Breakdown

How TAO Synergies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:TAOX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 261-2190
31 Mar 261-26100
31 Dec 250-2990
30 Sep 250-2771
30 Jun 250-2961
31 Mar 250-1351
31 Dec 240-1452
30 Sep 240-952
30 Jun 240-352
31 Mar 240-1252
31 Dec 230-1462
30 Sep 230-893
30 Jun 230-11104
31 Mar 230-4106
31 Dec 220-6106
30 Sep 220-1486
30 Jun 220-1496
31 Mar 220-1385
31 Dec 210-1384
30 Sep 210-1474
30 Jun 210-1574
31 Mar 210-1684
31 Dec 200-1583
30 Sep 200-1283

Quality Earnings: TAOX is currently unprofitable.

Growing Profit Margin: TAOX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TAOX is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.

Accelerating Growth: Unable to compare TAOX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TAOX is unprofitable, making it difficult to compare its past year earnings growth to the Software industry (27.2%).


Return on Equity

High ROE: TAOX has a negative Return on Equity (-96.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/16 23:31
End of Day Share Price 2026/09/16 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TAO Synergies Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide